SARS-CoV-2 and innate immunity: the good, the bad, and the "goldilocks".

Sievers, Benjamin L; Cheng, Mark T K; Csiba, Kata; Meng, Bo; Gupta, Ravindra K

Sievers, Benjamin L; Cheng, Mark T K; Csiba, Kata; Meng, Bo; Gupta, Ravindra K.

Afiliação

Sievers BL; Department of Medicine, University of Cambridge, Cambridge, UK.
Cheng MTK; Department of Medicine, University of Cambridge, Cambridge, UK.
Csiba K; Department of Medicine, University of Cambridge, Cambridge, UK.
Meng B; Department of Medicine, University of Cambridge, Cambridge, UK. bm432@cam.ac.uk.
Gupta RK; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, UK. bm432@cam.ac.uk.

Cell Mol Immunol ; 21(2): 171-183, 2024 02.

Article em En | MEDLINE | ID: mdl-37985854

Assuntos

COVID-19; SARS-CoV-2; Humanos; Vacinas contra COVID-19; Síndrome de COVID-19 Pós-Aguda; Imunidade Inata

Palavras-chave

Antiviral targets; Cytokines; Inflammation; Innate immune response; Interferon; SARS-CoV-2

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google